Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

Vaccine effectiveness relies on creating a strong antibody response that can be reactivated to fight future infections.

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy.

Does a claim that merely recites an inherent property of an otherwise obvious claim require an additional analysis to demonstrate that a person ...

Wexford-based biopharmaceutical company Coeptis Inc. announced the formation of GEAR Therapeutics, a majority-owned ...

Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected ...

MediLink Therapeutics Ltd. is exploring a licensing partnership to develop an antibody-drug conjugate with a global ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

Pierre Fabre SA and Redridge Bio AG have signed an exclusive R&D collaboration and license agreement to identify and develop ...

SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral ...

Vaccine effectiveness relies on creating a strong antibody response that can be reactivated to fight future infections. Now, ...